Novavax Receives SARS Vaccine Funding From NIH

Novavax, a specialty pharmaceutical company, has received a three-year contract from NIH to develop a Severe Acute Respiratory Syndrome (SARS) vaccine using its proprietary Virus Like Particle (VLP) technology. The grant for $1,069,789 over three years will assist Novavax in its development of a VLP vaccine for proof of concept studies in preparation for human trials.

Yahoo News (http://biz.yahoo.com/prnews/050204/nyf046_1.html)